Inhaled corticosteroid/long-acting beta-agonist combination classes
Breztri is an inhaled fixed-dose triple therapy that contains an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA). [1] Advair is an inhaled fixed-dose dual therapy that contains an ICS and a LABA. [2] Breyna is an inhaled fixed-dose dual therapy that contains an ICS and a LABA. [3]
Medication selection algorithm
- Inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) dual therapy (examples: Advair, Breyna). [2]
- Inhaled corticosteroid/long-acting beta-agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) triple therapy (example: Breztri). [1]
Combination composition
- Breztri contains budesonide (ICS), glycopyrrolate (LAMA), and formoterol (LABA). [1]
- Advair contains fluticasone (ICS) and salmeterol (LABA). [2]
- Breyna contains budesonide (ICS) and formoterol (LABA). [3]
Monotherapy versus combination therapy
- Advair and Breyna are dual-combination inhalers that provide two pharmacologic components: ICS plus LABA. [2]
- Breztri is a three-component inhaler that adds a third pharmacologic component: LAMA. [1]
Key clinical distinction between the “same class” question
- Breztri is not the same inhaler class as Advair or Breyna because Breztri includes a LAMA in addition to the ICS and LABA. [1]
- Advair and Breyna share the same core inhaler class as ICS/LABA dual therapy. [2]
Targets or goals of therapy
- These inhalers are maintenance bronchodilator and anti-inflammatory therapies used to prevent symptoms and exacerbations in chronic obstructive pulmonary disease (COPD) based on their labeled medication combinations. [1]
Common pitfalls to avoid
- Treating Breztri as interchangeable with Advair or Breyna is incorrect because Breztri delivers triple therapy (ICS/LABA/LAMA) rather than dual therapy (ICS/LABA). [1]